A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 145 participants.

Also called NCT04074551

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 145 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04074551
Other papers using this trial's data
  • A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia American journal of cardiovascular drugs : drugs, devices, and other interventions, 2023-07 DOI, PubMed 37395974, PMC10328852 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04074551. Randomized; double masking; primary purpose treatment. Start 2019-07-16 (actual); primary completion 2020-03-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
Condition
Hypertension
Condition
Dyslipidemias
Intervention (Drug)
HCP1701
Intervention (Drug)
Losartan
Intervention (Drug)
Amlodipine
Intervention (Drug)
Rosuvastatin and Ezetimibe
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct04074551
Content hash
ed544159cd5be02224c14201b173939b655940bd4e53cab7e19f9253f2db847a